Home›Stock Screener›Global Health›Intrinsic Value

Global Health Intrinsic Value

Global Health intrinsic value. Global Health (MEDANTA) median intrinsic value is ₹1475.56 from 10 valuation models (range ₹443–₹2919), vs current price ₹1478.30 — -0.2% downside (Trading Near Calculated Value), margin of safety -0.2%. Browse MEDANTA balance sheet details for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹1478.30
Primary Intrinsic Value
₹722.48
Market Cap
₹7983 Cr
-0.2% Downside
Median Value
₹1475.56
Value Range
₹443 - ₹2919
Assessment
Trading Near Calculated Value
Safety Margin
-0.2%

MEDANTA Valuation Methods Summary — DCF, Graham Number & P/E

Global Health intrinsic value across 10 models vs current price ₹1478.30 — upside/downside and value range per method. For current market price and key ratios, visit Global Health share price today.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹722.48 ₹577.98 - ₹866.98 -51.1% EPS: ₹32.84, Sector P/E: 22x
Book Value Method asset ₹1475.56 ₹1328.00 - ₹1623.12 -0.2% Book Value/Share: ₹737.78, P/B: 2.0x
Revenue Multiple Method revenue ₹2211.85 ₹1990.66 - ₹2433.04 +49.6% Revenue/Share: ₹1105.93, P/S: 2.0x
EBITDA Multiple Method earnings ₹2918.52 ₹2626.67 - ₹3210.37 +97.4% EBITDA: ₹1576.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹1796.02 ₹1436.82 - ₹2155.22 +21.5% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹443.49 ₹399.14 - ₹487.84 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹507.38 ₹456.64 - ₹558.12 -65.7% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹2595.56 ₹2336.00 - ₹2855.12 +75.6% ROE: 22.0%, P/E Multiple: 16x
Graham Defensive Method conservative ₹738.34 ₹664.51 - ₹812.17 -50.1% EPS: ₹32.84, BVPS: ₹737.78
Dividend Yield Method dividend ₹443.49 ₹399.14 - ₹487.84 -70.0% DPS: ₹0.50, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

MEDANTA Intrinsic Value vs Market Price — All Valuation Models

Global Health fair value range ₹443–₹2919 vs current market price ₹1478.30 across 10 valuation models. Analyse MEDANTA shareholding pattern to track promoter, FII and institutional holdings.

MEDANTA Intrinsic Value Analysis — Undervalued or Overvalued?

Global Health median intrinsic value ₹1475.56, current price ₹1478.30 — Trading Near Calculated Value by 0.2%, margin of safety -0.2%.

What is the intrinsic value of MEDANTA?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Global Health (MEDANTA) is ₹1475.56 (median value). With the current market price of ₹1478.30, this represents a -0.2% variance from our estimated fair value.

The valuation range spans from ₹443.49 to ₹2918.52, indicating ₹443.49 - ₹2918.52.

Is MEDANTA undervalued or overvalued?

Based on our multi-method analysis, Global Health (MEDANTA) appears to be trading near calculated value by approximately 0.2%.

MEDANTA Financial Health — Key Ratios vs Industry Benchmarks

Global Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 22.0% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 25.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 1.01x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

MEDANTA Cash Flow Quality — Operating & Free Cash Flow

Global Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹714 Cr ₹170 Cr Positive Free Cash Flow 7/10
March 2025 ₹624 Cr ₹264 Cr Positive Free Cash Flow 7/10
March 2024 ₹612 Cr ₹392 Cr Positive Free Cash Flow 8/10
March 2023 ₹645 Cr ₹474 Cr Positive Free Cash Flow 8/10
March 2022 ₹311 Cr ₹101 Cr Positive Free Cash Flow 7/10